Astemizole Sensitizes Adrenocortical Carcinoma Cells to Doxorubicin by Inhibiting Patched Drug Efflux Activity

Area of Science:

• Oncology
• Pharmacology

Background:

• Adrenocortical carcinoma (ACC) has a high risk of relapse and metastasis, with limited treatment improvements.
• The Hedgehog receptor Patched (PTCH) contributes to doxorubicin efflux and treatment resistance in ACC.
• PTCH utilizes proton motive force for drug efflux, offering cancer-specific targeting with potentially reduced toxicity.

Purpose of the Study:

• To identify novel inhibitors of Patched-mediated drug efflux in Adrenocortical carcinoma.
• To evaluate the efficacy of astemizole in combination with doxorubicin for ACC treatment.

Main Methods:

• In vitro assessment of astemizole's effect on ACC cells.
• Evaluation of doxorubicin efflux inhibition by astemizole.
• Analysis of combined effects of astemizole and doxorubicin on ACC cell cytotoxicity, apoptosis, proliferation, and clonogenicity.

Main Results:

• Astemizole inhibits Patched-mediated drug efflux in ACC cells.
• Astemizole enhances doxorubicin's cytotoxic, proapoptotic, antiproliferative, and anticlonogenic effects.
• Low-dose astemizole sensitizes ACC cells to doxorubicin, increasing treatment effectiveness.

Conclusions:

• Astemizole is a novel inhibitor of Patched drug efflux.
• Combining astemizole with doxorubicin shows promise for enhancing ACC treatment efficacy.
• Astemizole combined with the standard EDPM regimen could reduce side effects and improve outcomes in ACC patients.